Literature DB >> 11137237

Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein.

G P Bembridge1, N Rodriguez, R Garcia-Beato, C Nicolson, J A Melero, G Taylor.   

Abstract

Complete protection against respiratory syncytial virus (RSV) infection was induced in mice vaccinated on two occasions with 2.5 microg of DNA, encoding the fusion (F) protein of RSV, precipitated onto gold microbeads. In contrast, immunisation with DNA encoding the attachment (G) protein of RSV resulted in a significant reduction in viral load following infection, but did not afford complete protection. Gene gun delivery of DNA-F elicited a T helper-2 (Th2) biased immune response that could not be modulated by the co-delivery of plasmids encoding IL-2, IL-12 or IFNgamma. Similarly gene gun delivery of DNA-G primed a Th2 response. Thus, all gene gun vaccinated mice produced a predominant Th2 biased pulmonary immune response characterised by the production of IL-4 and IL-5 with little IFNgamma following RSV challenge. Analysis of bronchoalveolar lavage (BAL) cells, 5 days post challenge, indicated that there was only a two-fold increase in the number of inflammatory cells in vaccinated compared with control animals. Despite the strong Th2 cytokine bias of lung lymphocytes and the predominant recruitment of CD4(+) T cells, following challenge, there was not a marked pulmonary eosinophilic response (range from 2 to 7% of BAL). In contrast, the BAL from mice vaccinated with control plasmid contained significantly more eosinophils than any other group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11137237     DOI: 10.1016/s0264-410x(00)00344-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus.

Authors:  Wendy Fonseca; Makoto Ozawa; Masato Hatta; Esther Orozco; Máximo B Martínez; Yoshihiro Kawaoka
Journal:  Arch Virol       Date:  2013-12-01       Impact factor: 2.574

Review 2.  Respiratory syncytial virus vaccine development.

Authors:  Yoshihiko Murata
Journal:  Clin Lab Med       Date:  2009-12       Impact factor: 1.935

3.  Immunogenicity and protective efficacy of a dual subunit vaccine against respiratory syncytial virus and influenza virus.

Authors:  Min-Hee Park; Jun Chang
Journal:  Immune Netw       Date:  2012-12-31       Impact factor: 6.303

4.  Need for a safe vaccine against respiratory syncytial virus infection.

Authors:  Joo-Young Kim; Jun Chang
Journal:  Korean J Pediatr       Date:  2012-09-14

5.  Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps.

Authors:  Nicola Ternette; Daniela Stefanou; Seraphin Kuate; Klaus Uberla; Thomas Grunwald
Journal:  Virol J       Date:  2007-06-05       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.